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Mesenchymal stem cells have the capacity to maintain immune homeostasis and 
prevent autoimmunity. We recently reported that human-derived gingival mesenchy-
mal stem cells (GMSCs) have strong capacity to suppress immune responses and 
T cell-mediated collagen-induced arthritis in animals. However, it is unclear whether these 
cells can suppress human T cell-mediated diseases. Here, we used a xenogenic GVHD 
model in the NOD/SCID mouse, which is a useful preclinical construct for evaluating 
the therapeutic and translational potential of this approach for applications in human 
disease. We found that GMSCs potently suppressed the proliferation of PBMC and 
T cells in vitro. Co-transfer of GMSC with human PBMC significantly suppressed human 
cell engraftment and markedly prolonged the mouse survival. Moreover, we demon-
strated that GMSCs inhibited human PBMC-initiated xenogenic responses via CD39/
CD73/adenosine and IDO signals. These findings suggest the potential for GMSCs to 
suppress human immune responses in immune system-mediated diseases, offering a 
potential clinical option to be used for modulating GVHD and autoimmune diseases.
Keywords: gingival mesenchymal stem cell, gVhD, indoleamine 2,3-dioxygenase, cD39, cD73, adenosine, 
immune regulation
inTrODUcTiOn
Allogenic graft-versus-host disease (allo-GVHD) is a severe complication of organ or bone marrow 
(BM) transplantation, which causes significant morbidity and mortality (1). The current strategies 
to treat allo-GVHD usually fail to achieve a long-lasting response (2, 3).
The successful engraftment of human cells to mouse (human to immunodeficient mouse chimera) 
also results in xenogenic GVHD (xeno-GVHD) that largely leads to fatal syndromes in NOD/SCID 
mice (4). Xeno-GVHD model provides an ideal preclinical tool to study the function and efficacy of 
human cells in vivo prior to studies in humans.
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Mesenchymal stem cells (MSCs) are stromal cell progenitors 
with the ability to differentiate down mesodermal cell lineages (5). 
They also have wide-ranging immunomodulatory properties that 
contribute to anti-inflammatory effects (6–8). Most frequently 
investigated MSCs are those derived from BM, adipose, and 
umbilical tissues (9, 10). Nonetheless, each MSC population has 
weaknesses. For example, BM-MSCs from patients with autoim-
mune diseases are dysfunctional, limiting the use of autologous 
MSCs for disease treatment. Use of BM-MSCs with long term 
has a potential risk on tumorigenesis (11–13) and did not achieve 
effective results for disease treatment (14). Invasive procures, 
pain, and infection risk also restrain the use of BM-MSCs and 
adipose-MSCs. Very limited cell yields are a weakness for use of 
umbilical tissue-derived MSCs.
We and others have recently reported that human gingival 
tissue-derived MSCs (GMSCs) shared similar phenotypic and 
functional characteristics as other MSCs in multiple animal 
experimental models, including colitis, collagen-induced 
arthritis, wound healing, and contact hypersensitivity (15–18). 
However, the effect of human GMSCs on human immune cell-
mediated diseases has not been previously reported.
In this paper, we present evidence that adoptive transfer of 
human GMSC markedly inhibits the development of xeno-GVHD 
through a mechanism involving indoleamine 2,3-dioxygenase 
(IDO) and CD39/CD73/adenosine signals. The results suggest 
that manipulation of GSMC provides a promising approach to 
treatment of human immunological diseases.
MaTerials anD MeThODs
animals
NOD/SCID mice were purchased from the Jackson Laboratory. 
This study was carried out in accordance with the recommen-
dations of the Institutional Animal Care and Use Committees 
(IACUC) approved by at the Sun Yat-sen University, the 
University of Southern California and the Penn State University 
Hershey Medical Center.
gingiva-Derived Mscs
Human gingiva samples were collected following routine dental 
procedures at the Division of Dentistry in the Third Hospital at 
Sun Yat-sen University and the School of Dentistry of USC, which 
were approved by the medical ethics committees of Institutional 
Review Boards (IRB) at the Third Hospital at the Sun Yat-sen 
University and the Keck School of Medicine at the University of 
Southern California and at the Penn State University Hershey 
Medical Center. The written informed consent was obtained from 
the donors. The transfer of gingival tissues from the University of 
Southern California to the Penn State University Hershey Medical 
Center was approved by both institutions. Human GMSCs were 
prepared from these samples as previously described (15, 19). 
BMSCs were obtained from ATCC (PCS-500-012).
immune cell isolation and Preparation
CD3+ T cells were prepared from human PBMCs as described 
before (20). Non T cells were preserved and irradiated with 
30  cGy using a 137Cs source and served as antigen-presenting 
cells. CD4+CD25+ nTreg cells were acquired from T cells by cell 
sorting, gating on CD4+CD25brightCD127− cell population, with 
>99% purity of the selected population.
gMscs immunosuppression assays
GMSC or GMSCs pretreated with indicated reagents were 
cocultured with CD3+ T cells, ratio of GMSC to T cells was 
1:5. Different reagents, including selective heme oxygenase1 
(HO-1) inhibitor [50  ng/ml zinc protoporphyrin IX (ZnPP); 
Frontier Scientific], HO-1 inducer (50  ng/ml hemin; Sigma-
Aldrich), nitric oxide (NO) synthase inhibitor [1  mM l-NG 
nitroarginine methyl ester hydrochloride (l-NAME); Sigma-
Aldrich], indoleamine 2,3-dioxygenase (IDO) inhibitor [500 μM 
l-1-methyltryptophan (1-MT); Sigma-Aldrich], CD73 inhibitor 
[100–500  µM α,β-methylene ADP (APCP); Sigma-Aldrich], a 
CD39 inhibitor [100 µM sodium polyoxot-ungstate 1 (POM1); 
Tocris Bioscience], selective cyclooxygenase 1 (COX-1) inhibitor 
(20 µM indomethacine; Sigma-Aldrich), selective COX-2 inhibi-
tor (10 µM NS398; Tocris Bioscience), ALK5 inhibitor (10 µM), 
anti-transforming growth factor β (anti-TGF-β) antibody 
(10 µg/ml; BD PharMingen), selective A2B adenosine receptor 
antagonist (10  µM alloxazine; Sigma-Aldrich), selective A2A 
adenosine receptor competitive antagonist (25  µM SCH58261; 
Tocris Bioscience), were added to the coculture system, and the 
suppression rate was determined by Flow Cytometry. To exclude 
the non-specific role of these inhibitors to T responder cells, we 
have added various inhibitors to baseline alone and GMSC group 
was compared to each baseline. In other experiments, PBMCs 
were stimulated with lipopolysaccharides (LPS) (100 ng/ml) with 
a ratio of PBMCs to GMSCs at 1:5. After 3  days, intracellular 
cytokines including IL-4, IL-17, and IFN-γ positive cells were 
determined in CD4+ T cells by FACS (21).
Development of Mouse Xeno-gVhD Model
Mice were irradiated by 2.5 cGy TBI using a 137Cs source 2–4 h 
before PBMC injection. CD25-depleted PBMC (20 × 106) were 
injected intravenously into mice via tail vein. Four hours later, 
PBS, GMSCs, human Fibroblasts, or nTregs were intravenously 
co-transfused. Mice were monitored every 2–3 days for weight 
loss and assessed for symptoms of GVHD. Blood samples were 
taken weekly to detect the percentages of human CD3+ T cells and 
cytokine production and Foxp3 expression among CD4+ cells. 
Serum samples were used to measure cytokines and antibod-
ies by ELISA. At the terminal point of observation, mice were 
sacrificed for cytokine measurements and histologic analysis. 
To determine the underlying mechanisms, a tryptophan analog 
1-Methyl-d-tryptophan (1-MT) (Sigma) was administered i.p. at 
10 mg/mouse/day for 14 consecutive days. Additionally, GMSCs 
cells were pretreated with POM-1 (Tocris Bioscience; 100 µM) 
overnight before being injected into mice.
statistical analysis
Data are represented as mean ±  SEM. Multiple regression and 
Student’s t-test were used for statistical analysis. The mouse sur-
vival was determined by the Kaplan–Meier log-rank test. p < 0.05 
was considered to be significant.
FigUre 1 | gMscs inhibit T cell proliferation through cD39/cD73 and iDO signals. (a,B) Human CD3+ T cells were prepared from PBMC and labeled with 
CFSE. T cells were then stimulated with irradiated non T cells (1:4) and anti-CD3 (1 µg/ml) for 4 days. Human fibroblast cells were used as a negative control. The 
T cell proliferation was determined by Flow cytometry. A representative experiment is shown in panel (B). (c) GMSCs were cocultured with CD3+ T cells as 
described above. Graded doses of GMSCs were added to T cells for 4 days. (D) GMSC were cocultured with CD3+ T cells, ratio of GMSC to T cells was 1:5. 
Different reagents as described above were added to the coculture system, and the suppression rate was determined by Flow cytometry. The same ratio of GMSC 
and reagents were added as in panels (c,D). CFSE dilution was determined by FACS. Data are summarized from three replicate experiments, represented as 
mean ± SEM. **p < 0.01, ***p < 0.001 versus the own control group containing each inhibitor in baseline well.
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resUlTs
gMscs suppress human immune 
responses through cD39/73/adenosine 
and iDO signals but independent of 
Foxp3+ Treg cells In Vitro
We have previously shown that human GMSCs display the 
typical morphologic and phenotypic characteristics of MSCs 
and suppress mouse immune responses (19). Now, we dem-
onstrate that GMSCs are able to suppress both human CD3+ 
and CD4+ T cells proliferation in vitro, while the control cells, 
human fibroblasts, did not display such suppressive ability 
(Figures 1A,B). The ratio of 1:1 of GMSCs to T cells resulted 
in 80% suppression of T cell proliferation, and the suppression 
appeared to have a dose-dependent effect (Figure 1C). Unlike 
other MSCs that require HO-1, iNOS, TGF-β, or PGE2 to sup-
press immune responses (7, 22), unexpectedly, we found that 
GMSCs inhibited human lymphocytes proliferation through 
CD39/CD73/adenosine and/or IDO signals in vitro (Figure 1D). 
Since various inhibitors and antagonists possibly directly alter T 
cell proliferation or indirectly through non-specific role change 
T cell proliferation, we have added each inhibitor or antagonist 
to T cell proliferation alone to exclude these roles. We observed 
that addition of 100 µM CD39 inhibitor markedly abolished the 
suppressive effect of GMSCs on T cell proliferation (Figure 1D); 
this dose of CD73 inhibitor did not abolish until its doses were 
raised to 200–500  µM. It is likely that both inhibitors have a 
different sensitivity. We also revealed that either A2A or A2B 
adenosine receptor antagonist did not change GMSCs function; 
nonetheless, when the both adenosine receptor antagonists 
were combined, it significantly revised the inhibitor func-
tion of GMSCs to T cells (Figure  1D), thus A2A or A2B can 
compensate each other. We have pretreated GMSCs and then 
cocultured these GMSCs with T cells, the results are similarly 
observed (data not shown), further validating that these chemi-
cal inhibitors/antagonists do not directly exert their role in T 
cells. GMSCs express CD39 and CD73 and both are crucial for 
the degradation of ATP, AMP to generate adenosine that binds 
both A2A and A2B receptors to initiate immune regulatory effect 
(23), while IDO is only upregulated in the GMSCs cultured in 
the presence of IFN-γ or activated T cells (18, 19, 22).
It has been reported that Toll-like receptor 4, which is a major 
receptor for LPS, was indispensable in the pathogenesis of GVHD 
(24), and LPS stimulation results in the release of pro-inflamma-
tory cytokines from human peripheral cells (25). We, therefore, 
analyzed the inflammatory cytokine production following LPS 
stimulation and found that GMSCs markedly inhibited the secre-
tion of IFN-γ, IL-4, and IL-17 by lymphocytes in this condition 
(Figures 2A,B). The production of pro-inflammatory cytokines 
FigUre 2 | gMscs inhibit Th1 and Th17 production, but show no effect on the Foxp3 induction in vitro. PBMC were cocultured with GMSC for 3 days 
under the stimulation of lipopolysaccharides (100 ng/ml) with a GMSC to PBMC ratio of 1:5. Intracellular cytokines IL-4, IL-17, IFN-γ among CD4+ cells were 
analyzed by flow cytometry. Shown are representative flow data (a) and frequencies of each cytokine on the gate of CD4+ cells (B). Experiments were repeated 
three times. (c) Human naïve CD4+ T cells were cocultured with or without GMSC or human fibroblast cells (1:5) and stimulated with anti-CD3/CD28 microbeads 
(beads: T cells ratio = 1:5) with or without TGF-β, IL-2 for 5 days. Foxp3 expression on CD4+ T cells was analyzed by flow cytometry. Data are presented as the 
mean ± SEM from three independent experiments.
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was one of the important mechanisms involved in the patho-
genesis of GVHD (3), providing further evidence that GMSCs 
may suppress GVHD. Furthermore, CD4+Foxp3+ Treg cells 
have a potent immunoregulatory role and can suppress GVHD 
(4, 26–28), so we also sought to determine whether GMSCs can 
suppress GVHD through Foxp3 upregulation. However, GMSCs 
did not change Foxp3 expression in CD4+ T cells irrespective of 
the presence of TGF-β in vitro (Figure 2C).
gMscs suppress Xeno-gVhD In Vivo
We, next, analyzed the immunosuppressive capacity of GMSCs 
in vivo in a human to mouse immunodeficient chimera, a xeno-
geneic GVHD model. As reported previously, transfer of human 
CD25-depleted PBMC to NOD/SCID mouse results in a typical 
GVHD syndrome, including weight loss, elevated human pro-
inflammatory cytokines, anti-human antibodies, and death of the 
host animal at around 2  weeks (29, 30). Cotransfer of GMSCs 
(5 ×  106) with CD25-depleted PMBCs (20 ×  106) significantly 
prolonged mouse survival from 15.8 ± 3.76 to 46.0 ± 12.0 days 
(Figure 3A). Correspondingly, GMSC transfusion resulted in a 
significantly lower expansion of human T cells in the mouse and 
significantly prevented weight loss (Figures 3B,C). Furthermore, 
HE staining demonstrated that the pathological changes and 
inflammation degrees including necrosis and lymphocyte infil-
tration present in liver, lung, and intestine were much less in 
GMSCs-treated mice than in control-treated mice (Figures 3D,E). 
Accordingly, GMSCs infusion significantly inhibited production 
by the engrafted human CD4+ cells of IFN-γ, IL-4, IL-17, and 
TNF-α compared to control fibroblasts (Figure  3F). GMSCs 
did not change IL-10 production and did not suppress IL-2, but 
rather promoted IL-2 production (Figure 3F). GMSC infusion 
did not promote Foxp3+ cell frequency in donor human CD4+ 
cells (data not shown).
cD39 and iDO signals contribute to the 
suppression of gMscs on Xeno-gVhD 
In Vivo
To identify the mechanism of GMSC function in xeno-GVHD 
in  vivo, we analyzed the role of CD39 and IDO signals, since 
they played a critical role in  vitro (Figures  1D,E). We selected 
CD39 blockade since CD39 markedly affects GMSC function 
in vitro and is source of CD39/CD73/adenosine signal pathway. 
Interestingly, CD39 inhibition with POM-1 or IDO inhibition 
by 1-MT almost completely abolished the suppressive effect of 
GMSCs on xeno-GVHD model (Figures 4A,B). We have used 
FigUre 3 | gMscs inhibit xenogenic gVhD in nOD/sciD mice. Freshly isolated human CD25-depleted PBMCs (20 × 106) were injected into NOD/SCID mice 
intravenously. Mice were co-injected with PBS (n = 10), or 4 × 106 nTregs (n = 11), or 2 × 106 GMSCs (n = 11), or 2 × 106 fibroblasts (n = 10). GMSCs were 
obtained from different donors and used after 2–5 passages. (a) Survival of GVHD mice. (B) Peripheral blood was collected weekly and stained with anti-human 
CD3 antibodies and quantified by flow cytometry. (c) Average weight is shown as mean ± SEM. (D) Liver, lung, and intestine were collected at the time of mouse 
euthanization and evaluated by hematoxylin and eosin staining for histopathologic investigation. Representative pictures of livers, lungs, and intestines from naive 
mice model or GMSC-treated model are shown. Scale bars = 200 mm. (e) Histological scores were calculated by blinded pathologists and are shown as mean and 
SEM from groups of 10 mice (*p < 0.05, **p < 0.01). (F) When mice were euthanized in the end point of observation, the expression of cytokines by CD4+ splenic 
T cells was determined by intracellular cytokine staining via flow cytometry, for IL-2, IL-4, IL-10, IL-17, IFN-γ, and TNF-α. Foxp3 expression was also measured using 
intracellular flow cytometric analysis. Data are shown as mean ± SEM (n = 5 for each group, and experiments were repeated twice). *p < 0.05, **p < 0.01, 
***p < 0.001 stands for fibroblast versus GMSC-treated group. NS, not significant.
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continuously i.p. injection of 1-MT but not pretreatment, the key 
reason is that GMSCs can secrete IDO when they are stimulated 
with IFN-γ, while this cytokine is rapidly elevated in xeno-GVHD. 
Moreover, we have adopted the injection of 1-MT to xeno-GVHD 
model and showed that this administration did not significantly 
alter the courses and severities of xeno-GVHD (Figures 4C,D). 
Thus, the effect of 1-MT will be mainly associated with GMSCs. 
These results highlight the key role of CD39 and IDO in the 
immunosuppression mediated by GMSCs in human cell immune 
responses.
gMscs Displayed the superior effect to 
BMscs on suppressing Xeno-gVhD
Given the existence of differences among the various tissue-
derived MSCs, we further compared the functionality of GMSCs 
and BMSCs in the xeno-GVHD model. We conducted an experi-
ment to directly compare the effect of two MSC populations on 
xeno-GVHD. The experiments were carried out as described in 
Figure 3 with similar doses of BMSCs or GMSC cotransferred 
with human PBMC into NSG mice. As shown (Figure 5), while 
BMSCs infusion prolonged the survival twofold, GMSC infusion 
almost prolonged survival threefold. Accordingly, the weight loss 
and inflammatory pathology in liver, lung, and intestine were 
much less in GMSC-treated xeno-GVHD than in BMSCs-treated 
xeno-GVHD, although BMSC treatment did display effects on 
xeno-GVHD mice.
DiscUssiOn
We present evidence that human GMSCs markedly suppress 
human immune cell responses in  vitro and human immune 
FigUre 4 | gMscs inhibit xenogenic gVhD through cD39 and/or iDO signaling pathways. NOD/SCID mice were injected with 20 × 106 PBMC with or 
without 2 × 106 GMSCs (n = 8). (a,B) Some GMSC cells were pretreated with POM-1 (100 µm) overnight before co-injection with PBMC (n = 11). (c,D) In another 
group, mice giving human cell alone or human cells plus GMSCs were injected i.p. with 1-MT at 10 mg/mouse/day for 14 consecutive days (n = 10) and then 
monitored for survival and weight loss. Kaplan–Meier survival curves depict the percentage of live mice. (B,D) The weight loss data were presented as the 
Mean ± SEM from two independent experiments. **p < 0.01, ***p < 0.001 GMSC versus the control treated group.
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cell-mediated disease progress in a humanized animal xeno-
GVHD in vivo. To our knowledge, this is first demonstration that 
human GMSCs can ameliorate human cells-initiated diseases, 
displaying a potential promise for clinical therapy on autoim-
mune diseases, GVHD, and prevention of organ transplantation 
rejection.
We provide insight into potential functional consequences 
of our finding by identifying CD39/CD73/adenosine signal and 
IDO pathway as being involved in the regulatory effect of GMSCs. 
CD39 is an integral membrane protein that phosphohydrolyzes 
ATP, and less efficiently ADP, in a Ca2+- and Mg2+-dependent 
fashion, to yield AMP (31). CD39 is expressed on many human 
tissues and cells including immune cells that are important 
for immune homeostasis and function (32). CD39 is highly 
expressed on MSC, and it is likely that CD39 signal contributes to 
immunoregulatory effects of MSC (15). Combining with CD73, 
another ectonucleotidase that degrades AMP to adenosine, CD39 
acts as an immune regulatory factor by removing metabolic ATP 
and producing immune modulating adenosine (33). We previ-
ously have shown that CD39 is highly expressed on GMSCs and is 
needed for their suppressive activity in murine collagen-induced 
arthritis (19). Given CD39–CD73–adeniosin is a chain to develop 
immune regulatory molecule, adenosine, it is not surprising 
that CD73 and adenosine inhibitors also significantly revise the 
suppressive activity of GMSC. We also observed an interesting 
phenomenon that adenosine needs both receptors to exert its 
immuoregulatory role, since blockade of either A2A or A2B 
receptor did not significantly abolish the suppressive ability of 
GMSCs.
It is likely that CD39/CD73/adenosine may not be only signal 
pathway that contributes to immuosuppressive activity of GMSCs. 
Our findings also indicate that the blockade of IDO in GMSCs 
significantly abolished the suppression of GMSCs either in vitro 
or in  vivo in the xeno-GVHD model. It has been recognized 
that IDO offers an intriguing mechanism for achieving T  cell 
tolerance—it catabolizes the essential amino acid tryptophan, 
resulting in the generation of a putative pro-apoptotic agent, 
kynurenine, as well as other downstream immunomodulatory 
metabolites (7, 34).
IDO is not constitutively expressed by MSC, but can be signifi-
cantly induced by a variety of inflammatory mediators (29, 31). 
IFN-γ is one of these inflammatory mediators that is involved 
in cross-talk between MSC and immune cells. The xeno-GVHD 
produces a large amount of IFN-γ and TNF-α, which probably in 
turn stimulate GMSCs to produce IDO (4, 35). Previous study has 
indicated that GMSCs do not constitutively express IDO, but in 
response to IFN-γ stimulation, showed a significantly increased 
level of functional IDO (15). We recently have observed that 
GMSCs also enhance their immunoregulaotry function follow-
ing TNF-α stimulation (36). Currently, we do not know what the 
relationship between CD39 and IDO is, and this is a topic that 
deserves further study in the future.
It is reasonable that GMSCs suppress the production of 
multiple cytokines, since these mediators are crucial for disease 
FigUre 5 | gMscs are superior to BMscs in inhibiting xenogenic gVhD (xeno-gVhD) in nOD/sciD mice. Freshly isolated human CD25-depleted 
PBMCs (20 × 106) were injected into NOD/SCID mice intravenously. Mice were co-injected PBMC with PBS (n = 10), or 2 × 106 GMSC (n = 10), or 2 × 106 BMSC 
(n = 10). GMSCs were obtained from different donors and used after 2–5 passages. (a) Survival of GVHD mice. ***p < 0.001 BMSC versus model, or GMSC versus 
BMSC. (B) Average weight is shown as mean ± SEM. **p < 0.01 BMSC versus model, or GMSC versus BMSC. (c) Liver, lung, and small intestine were collected at 
the time of mouse euthanization and evaluated by hematoxylin and eosin staining for histopathologic features. Representative sections of liver, lung, and small 
intestine from model or BMSC- or GMSC-treated xeno-GVHD were shown (left panel). Histological scores were calculated by blinded pathologists and are shown as 
mean and SEM from groups of 10 mice. *p < 0.05, **p < 0.01, BMSC versus model or GMSC versus BMSC group. NS, not significant.
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progression and host mortality. GMSCs displayed significant 
suppression of Th1, Th2, and Th17 cells in either in  vitro or 
in vivo conditions. Nonetheless, current study does not rule out 
whether GMSCs can induce Tr1 or Foxp3+ Treg cells. As the 
NSG recipient lacks immune cells, this model does not permit 
determination of this possibility. Interestingly, GMSCs promote 
IL-2 production; detailed mechanisms are unclear, but this has 
therapeutic implications, since recent studies have indicated low 
doses of IL-2 can treat several immunological diseases, including 
GVHD (37, 38).
T regulatory cells are another immunosuppressive factor 
(39, 40), and some relationship between MSC and Treg cells 
has been identified (41, 42). We previously have reported that 
GMSCs can promote the induction of CD39+ Foxp3+ Treg cells 
in recipient mouse (43), although GMSCs did not promote Treg 
induction in the present study that is consistent with another 
report (44). Further determination of whether in fact Tregs are 
involved in vivo may require a clinical trial of GMSCs in human 
diseases.
An interesting observation in the current study is the finding 
that GMSCs are superior to BMSCs in controlling xeno-GVHD. 
BMSCs are widely used in clinical trials in patients with auto-
immune diseases (45–48). Nonetheless, the weaknesses with 
utilization of BMSCs are significant. First, an invasive approach 
is required to harvest BM cells. Second, BMSCs from patients 
with autoimmune diseases are dysfunctional which has limited 
the adoption of autologous BMSCs for treating diseases. Third, 
BMSCs are tumorigenic, resulting in a long-term risk of use.
GMSCs express a similar profile of cell surface molecules as 
BMSC. Additionally, the gingiva is a ready source of material, 
available in all patients and can be repeatedly sampled if neces-
sary. The cell proliferation in vitro is much faster in GMSCs than 
in BMSCs (15), ensuring the number required for clinical cell 
therapy. GMSCs are not tumorigenic, an additional advantage 
for their clinical application. Moreover, we recently observed that 
GMSCs isolated from active SLE and RA patients shared similar 
phenotypes and sustained immunoregulatory function similar to 
healthy controls (Zhang et al., unpublished observation). Thus, 
it is highly likely that the manipulation of autologous GMSCs 
represents a potential therapy strategy in human autoimmune 
diseases, GVHD, organ transplantation, and other immune 
system disorders.
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